Results 241 to 250 of about 152,115 (284)
Chemotherapy with bevacizumab and pembrolizumab followed by radiotherapy for unclassified round cell sarcomas of the gallbladder: A case report and review of literature. [PDF]
Transl OncolWang D +7 more
europepmc +1 more source
Nationwide Survival Impact of Bevacizumab Under National Reimbursement for Advanced Cervical Cancer in South Korea. [PDF]
Cancers (Basel)Kim J +5 more
europepmc +1 more source
Correction: Ficany et al. Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia. <i>J. Clin. Med.</i> 2025, <i>14</i>, 7724. [PDF]
J Clin MedFicany A +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nature Reviews Drug Discovery, 2005
Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target tumour angiogenesis.
Lee M. Ellis, Peter Kirkpatrick
openaire +2 more sources
Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target tumour angiogenesis.
Lee M. Ellis, Peter Kirkpatrick
openaire +2 more sources